RxDoctor Payments DataLook up a doctor →

Evan Schoenberg, MD

Ophthalmology · Atlanta, GANPI 1073747465

Payments from drug & device makers

$129,689in general payments, 2019–2025

Across 432 payments — averaging $300.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$46K
  • Glaukos Corporation$23K
  • AbbVie$21K
  • Johnson & Johnson Surgical Vision, Inc.$16K
  • Kala Pharmaceuticals, Inc.$7K
  • Rxsight Inc$3K
  • plus $14K from 30 others

What the payments were for

  • Consulting fees$46,68036%
  • Speaking & faculty fees$59,52646%
  • Travel & lodging$8,8397%
  • Food & beverage$14,51911%
  • Education$890%
  • Gifts$370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,689 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$437,251
Medicare patients
634
Services billed
2,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj44$1,246,303
XdemvyLotilaner22$39,973
RestasisCyclosporine14$22,409
CequaCyclosporine17$16,182
Fluorometholone126$11,163
MieboPerfluorohexyloctane/Pf13$9,785
Prednisolone Acetate216$8,432
ProlensaBromfenac Sodium21$7,035
CombiganBrimonidine Tartrate/Timolol13$6,490
Gatifloxacin108$4,372
Lotemax SmLoteprednol Etabonate11$4,166
FlarexFluorometholone Acetate31$4,083
ValacyclovirValacyclovir Hcl33$2,250
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,891
Ketorolac Tromethamine71$1,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$45,754$1,246,30344 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$316$39,97322 claims
AbbVieRestasis, Combigan$21,155$28,89927 claims
Sun Pharmaceutical Industries Inc.Cequa$852$16,18217 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$81$11,20132 claims
Bausch & Lomb Americas Inc.Miebo$240$9,78513 claims
Eyevance Pharmaceuticals LLCFlarex$2,018$4,08331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →